ERBB2 and osteosarcoma: T cells armed ex vivo (EAT) with the IgG-[L]-scFv-formatted GD2-BsAb (GD2-EATs) or HER2-BsAb (HER2-EATs) also successfully ablated both osteosarcoma cell-line-derived xenografts (CDXs) and patient-derived xenografts (PDXs) with significantly lower cytokine release while increasing the overall survival [62,91].